Q2 2024 |
25 |
$168M |
+$71.8M |
-$90.1M |
-$18.4M |
SLNO, SRPT, GERN, MRUS, INSM
|
13F-HR |
8/14/2024, 07:52 AM |
Q1 2024 |
22 |
$180M |
+$116M |
-$86.4M |
+$29.6M |
BPMC, SLNO, CGON, XENE, VRNA
|
13F-HR |
5/15/2024, 06:56 AM |
Q4 2023 |
22 |
$139M |
+$74M |
-$28.9M |
+$45.1M |
ARGX, SLNO, CBAY, XENE, ITCI
|
13F-HR |
2/14/2024, 07:30 AM |
Q3 2023 |
19 |
$85.2M |
+$46.9M |
-$37.3M |
+$9.62M |
MLTX, XENE, ITCI, AXSM, APLS
|
13F-HR |
11/14/2023, 03:09 PM |
Q2 2023 |
17 |
$82.6M |
+$39.2M |
-$36.5M |
+$2.74M |
RETA, VRNA, XENE, CYTK, GERN
|
13F-HR |
8/14/2023, 04:04 PM |
Q1 2023 |
18 |
$76.3M |
+$67.4M |
-$91.5M |
-$24M |
VRNA, XENE, BLU, CYTK, MDGL
|
13F-HR |
5/15/2023, 11:12 AM |
Q4 2022 |
30 |
$103M |
+$37.2M |
-$77.2M |
-$40M |
RARE, AADI, ACAD, MRSN, GLPG
|
13F-HR |
2/14/2023, 10:30 AM |
Q3 2022 |
39 |
$151M |
+$126M |
-$84.1M |
+$42.3M |
SGEN, RARE, SNY, KPTI, IRWD
|
13F-HR |
11/14/2022, 07:38 AM |
Q2 2022 |
22 |
$110M |
+$30.5M |
-$35.8M |
-$5.33M |
ARGX, MDVL, COGT, LNTH, GH
|
13F-HR |
8/15/2022, 09:39 AM |
Q1 2022 |
21 |
$132M |
+$13.1M |
-$121M |
-$108M |
LNTH, ISEE, GH, ARVN, COGT
|
13F-HR |
5/16/2022, 07:04 AM |
Q4 2021 |
30 |
$286M |
+$68.8M |
-$51.6M |
+$17.2M |
NTRA, ARVN, RGEN, ISO, FATE
|
13F-HR |
2/14/2022, 07:00 AM |
Q3 2021 |
29 |
$305M |
+$57.4M |
-$68.8M |
-$11.4M |
NTRA, RGEN, ARVN, MRTX, NUVB
|
13F-HR |
11/15/2021, 07:24 AM |
Q2 2021 |
27 |
$356M |
+$106M |
-$149M |
-$43.3M |
MDVL, NTRA, FATE, SYRS, ARVN
|
13F-HR |
8/16/2021, 08:30 AM |
Q1 2021 |
31 |
$413M |
+$87.1M |
-$51.6M |
+$35.5M |
AVIR, MDVL, CERE, SYRS, FATE
|
13F-HR |
5/17/2021, 07:35 AM |
Q4 2020 |
28 |
$388M |
$0 |
$0 |
|
MDVL, AVIR, CERE, SYRS, FATE
|
13F-HR |
2/16/2021, 07:21 AM |